Niagen Bioscience Inc. (NAGE) Stock Falls on Q1 2026 Earnings

Niagen Bioscience Inc. (NAGE) reported first-quarter 2026 results. Total revenue rose 3.3% year-over-year to $31.47 million, narrowly missing the estimate of $31.58 million. Gross profit increased 3.3% to $19.98 million, while operating profit fell 67.0% to $1.58 million. Net income attributable to common shareholders rose 24.8% to $6.32 million, and diluted earnings per share was $0.07, slightly below the consensus of $0.08.

Key income statement highlights:

Total revenue: $31.47 million (+3.3% YoY)

Gross profit: $19.98 million (+3.3% YoY)

Operating profit: $1.58 million (-67.0% YoY)

Net income: $6.32 million (+24.8% YoY)

Balance sheet and cash-flow snapshot:

Cash and cash equivalents: $66.55 million (+19.7% YoY)

Cash from operating activities: -$1.19 million (-115.2% YoY)

Purchases of property, plant and equipment: -$61,000 (+90.6% YoY)

Total liabilities: $32.00 million (+23.1% YoY)

Additional context: cost of sales totaled $11.50 million (+3.1% YoY). Market reaction showed shares of NAGE down 7.44% since market close. Overall, the quarter combined modest revenue growth and stronger net income with pressure on operating profit and operating cash flow, while cash balances improved.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Niagen Bioscience Inc. Insider Trading Activity

Niagen Bioscience Inc. insiders have traded $NAGE stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $NAGE stock by insiders over the last 6 months:

OZAN PAMIR (Chief Financial Officer) has made 2 purchases buying 6,685 shares for an estimated $45,616 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

Niagen Bioscience Inc. Hedge Fund Activity

We have seen 83 institutional investors add shares of Niagen Bioscience Inc. stock to their portfolio, and 93 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

STEELPEAK WEALTH, LLC added 3,373,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $14,874,930
VANGUARD GROUP INC removed 735,152 shares (-18.3%) from their portfolio in Q4 2025, for an estimated $4,675,566
ACADIAN ASSET MANAGEMENT LLC removed 547,261 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,480,579
NUVEEN, LLC removed 368,692 shares (-74.9%) from their portfolio in Q1 2026, for an estimated $1,625,931
MORGAN STANLEY added 351,753 shares (+66.6%) to their portfolio in Q4 2025, for an estimated $2,237,149
SEI INVESTMENTS CO added 348,423 shares (+1100.7%) to their portfolio in Q4 2025, for an estimated $2,215,970
HILLSDALE INVESTMENT MANAGEMENT INC. removed 320,272 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,036,929

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.